Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US-India Healthcare Summit: New Business Models Needed To Reach the World's Poor

This article was originally published in The Pink Sheet Daily

Executive Summary

The "bottom of the pyramid" represents a huge opportunity for Western companies, but they need to overcome hurdles to maximize the potential - and to fend off competitors emerging from around the world.

You may also be interested in...



Pfizer Delves Deeper In Generics Partnership With Strides Arcolab

NEW DELHI - Pfizer has further expanded its generic drug portfolio by signing two more license and supply agreements with Strides Arcolab, just four months after Pfizer partnered with the Bangalore-based drug manufacturer to bring generic injectable and oral drugs to the U.S. market

Abbott Ups Emerging Markets Ante With Zydus Deal, Established Products Unit

The acquisition of Solvay's pharmaceutical unit, completed in February, gave Abbott a substantial branded generics business and strengthened its international presence. Now the company is looking to build on those assets with an enhanced emerging market strategy

Pre-Competitive Collaboration Would Help Pharmaceutical Productivity Crisis - If Lawyers Could Get Out Of The Way

CAMBRIDGE, Mass. - Greater R&D collaboration was the theme of the day at the star-studded U.S.-India Chamber of Commerce biopharma and healthcare summit

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel